MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1643570-24-4
MCE 国际站:Elsubrutinib
产品活性:Elsubrutinib (ABBV-105) 是一种具有口服活性、有效的、有选择性和不可逆的 Bruton's tyrosine kinase (BTK) 抑制剂。Elsubrutinib 对 BTK 催化结构域的 IC50 为 0.18 μM。Elsubrutinib 可用于炎症性疾病的研究。
研究领域:Protein Tyrosine Kinase/RTK
作用靶点:Btk
In Vitro: Elsubrutinib inhibits BTK (C481S) with an IC50 of 2.6 μM, indicating a significant loss in potency upon exchanging the targeted thiol nucleophile with an alcohol, suggesting Cys481 is important in the manner in which Elsubrutinib inhibits BTK. Elsubrutinib irreversibly inhibits BTK enzyme activity and blocks BTK-dependent cellular activation. Elsubrutinib inhibits histamine release from IgE-stimulated basophils and IL-6 release from IgG-stimulated monocytes, which utilize Fce and Fcc receptors respectively. Elsubrutinib inhibits IgM-mediated B cell proliferation, which is dependent on signaling through the BCR. Elsubrutinib also inhibits TNF-release from CpG-DNA stimulated PBMCs, which signals through TLR9, although it does not inhibit the function of TLRs that do not use ITAM motifs, namely, TNF release from PBMCs stimulated either through TLR4 (with LPS) or through TLR7/8 (with R848). Elsubrutinib has significant impacts on IgM-mediated B cell proliferation.
In Vivo: Elsubrutinib (10 mg/kg; p.o.) inhibits antibody responses to NP-Ficoll and NP-KLH, but not to NP-LPS or Prevnar-13.
Elsubrutinib (0.1~10 mg/kg; p.o.) results in dose-dependent inhibition of paw swelling throughout the course of disease and significantly prevents the onset of proteinuria and prolongs survival at the 10 mg/kg QD and BID doses, while lower doses does not significantly inhibit these endpoints.
Elsubrutinib demonstrates exposure-dependent inhibition of increases in paw volume. Elsubrutinib significantly inhibits bone volume loss in a dose dependent manner consistent with the observed anti-inflammatory effects.
相关产品:Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Clinical Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | Anti-Blood Cancer Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Cysteine Targeted Covalent Library | Cysteine Targeted Covalent Fragment Library | Highly Selective Inhibitors Library | Atuzabrutinib | PCI 29732 | JAK3/BTK-IN-6 | Pirtobrutinib | CNX-500 | BTK inhibitor 17 | Remibrutinib | RN486 | GDC-0834 Racemate | Spebrutinib besylate | BTK inhibitor 19 | BMX-IN-1 | BMS-935177 | Ibrutinib | PF-06250112 | QL-X-138 | SJF620 hydrochloride | PROTAC BTK Degrader-2 | BTK-IN-8 | JAK3/BTK-IN-3 | JS25 | JAK3/BTK-IN-2 | (R)-Zanubrutinib | Edralbrutinib | Branebrutinib | Poseltinib | BTK inhibitor 20 | RET-IN-14 | QL47 | BTK-IN-23
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。